Earnings call transcript: Edwards Lifesciences Q1 2026 beats expectations

Edwards Lifesciences reported strong Q1 2026 financial results, surpassing analyst expectations with adjusted EPS of $0.78 and revenue of $1.65 billion. The company raised its full-year sales growth guidance to 9%-11% and adjusted EPS guidance to $2.95-$3.05, driven by robust performance in TAVR and TMTT product lines. Executive commentary highlighted a commitment to innovation and patient care, with sustained growth expected from strategic investments and a strong product pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin